Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses

OBJECTIVE: Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleot...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Burmester, James K., Berg, Richard L., Glurich, Ingrid, Yale, Steven H., Schmelzer, John R., Caldwell, Michael D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Marshfield Clinic 2011
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251364/
https://ncbi.nlm.nih.gov/pubmed/21562135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.951
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia